argenx Sponsored Webinar: An Evolving Understanding of CIDP Pathophysiology and the Science of FcRn Inhibition in CIDP

Join our experts as they discuss the evolving understanding of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pathophysiology and the science behind neonatal Fc receptor (FcRn) inhibition. The experts will share insights on the following topics through a presentation and panel discussion:

• Clinical overview of the pathophysiology and the potential role of autoantibodies in the disease biology of CIDP
• Role of FcRn on CIDP pathophysiology and the scientific rationale for FcRn blockade
• Overview of the current treatment landscape for CIDP
• Discussion on switching from IVIg to efgartigimod in the ADHERE trial and ongoing Phase 4 trial
• Clinical considerations for the use of efgartigimod in the management of CIDP